Copyright
©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 602-611
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.602
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.602
Table 2 End of treatment biopsy compared to prior to treatment biopsy
| Patient number | Weeks from biopsy to treatment start | Prior to treatment inflammation grade | End of treatment | |
| Inflammation | ||||
| Grade | Change | |||
| 1 | 10 | 1 | 2 | ↑ |
| 5 | 14 | 2 | 1 | ↓ |
| 10 | 22 | 3 | 4 | ↑ |
| 11 | 18 | 3 | 4 | ↑ |
| 13 | 26 | 2 | 2 | ↔ |
- Citation: Ismail B, Benrajab KM, Bejarano P, Ruiz P, Sears D, Tzakis A, Zervos XB. Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy. World J Hepatol 2022; 14(3): 602-611
- URL: https://www.wjgnet.com/1948-5182/full/v14/i3/602.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i3.602